Clinical Trial

Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-\[18F\]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05472493
Lead Sponsor University of Calgary
Conditions Primary Aldosteronism
Enrollment 30 participants
Start Date 2023-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-24